Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor.
Ramanathan-Girish S, McColm J, Clements JM, Taupin P, Barrowcliffe S, Hevizi J, Safrin S, Moore C, Patou G, Moser H, Gadd A, Hoch U, Jiang V, Lofland D, Johnson KW. Ramanathan-Girish S, et al. Among authors: patou g. Antimicrob Agents Chemother. 2004 Dec;48(12):4835-42. doi: 10.1128/AAC.48.12.4835-4842.2004. Antimicrob Agents Chemother. 2004. PMID: 15561864 Free PMC article. Clinical Trial.
In vogue with venture.
Patou G. Patou G. Nat Biotechnol. 2011 Nov;29(11):967-9. Nat Biotechnol. 2011. PMID: 22175076 No abstract available.
Durable biochemical response and safety with oral octreotide capsules in acromegaly.
Samson SL, Nachtigall LB, Fleseriu M, Jensterle M, Manning PJ, Elenkova A, Molitch ME, Ludlam WH, Patou G, Haviv A, Biermasz NR, Giustina A, Strasburger CJ, Kennedy L, Melmed S. Samson SL, et al. Among authors: patou g. Eur J Endocrinol. 2022 Oct 26;187(6):733-741. doi: 10.1530/EJE-22-0220. Print 2022 Dec 1. Eur J Endocrinol. 2022. PMID: 36173649 Free PMC article. Clinical Trial.
Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial.
Fleseriu M, Dreval A, Bondar I, Vagapova G, Macut D, Pokramovich YG, Molitch ME, Leonova N, Raverot G, Grineva E, Poteshkin YE, Gilgun-Sherki Y, Ludlam WH, Patou G, Haviv A, Gordon MB, Biermasz NR, Melmed S, Strasburger CJ. Fleseriu M, et al. Among authors: patou g. Lancet Diabetes Endocrinol. 2022 Feb;10(2):102-111. doi: 10.1016/S2213-8587(21)00296-5. Epub 2021 Dec 22. Lancet Diabetes Endocrinol. 2022. PMID: 34953531 Clinical Trial.
Correction to: Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results.
Labadzhyan A, Nachtigall LB, Fleseriu M, Gordon MB, Molitch M, Kennedy L, Samson SL, Greenman Y, Biermasz N, Bolanowski M, Haviv A, Ludlam W, Patou G, Strasburger CJ. Labadzhyan A, et al. Among authors: patou g. Pituitary. 2021 Dec;24(6):954. doi: 10.1007/s11102-021-01177-w. Pituitary. 2021. PMID: 34347226 Free PMC article. No abstract available.
Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results.
Labadzhyan A, Nachtigall LB, Fleseriu M, Gordon MB, Molitch M, Kennedy L, Samson SL, Greenman Y, Biermasz N, Bolanowski M, Haviv A, Ludlam W, Patou G, Strasburger CJ. Labadzhyan A, et al. Among authors: patou g. Pituitary. 2021 Dec;24(6):943-953. doi: 10.1007/s11102-021-01163-2. Epub 2021 Jun 25. Pituitary. 2021. PMID: 34173129 Free PMC article. Clinical Trial.
48 results